Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 4:05 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 1,228 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: TBL 12 Clear all
Completed Phase 2 Interventional Results available

Safety and Efficacy of Sofosbuvir + Ribavirin in Adolescents and Children With Genotype 2 or 3 Chronic HCV Infection

NCT02175758
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
SOF, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
3 Years to 17 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
16
States / cities
Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2019 · Synced Nov 3, 2026, 4:05 PM EST
Withdrawn Phase 3 Interventional

Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease

NCT05082571
View directory record Official record
Conditions
Anemia of Chronic Kidney Disease
Interventions
vadadustat
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
4 Months to 16 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Nov 3, 2026, 4:05 PM EST
Completed Phase 2 Interventional

Study To Evaluate The Efficacy And Safety Of PH-797804 For 12 Weeks In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD) Taking Salmeterol Xinafoate/Fluticasone Propionate Combination

NCT01321463
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
PH-797804, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
40 Years to 80 Years
Enrollment
377 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
22
States / cities
Mobile, Alabama • Glendale, Arizona • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2013 · Synced Nov 3, 2026, 4:05 PM EST
Completed Phase 3 Interventional Results available

Efficacy and Safety of Famciclovir 1-day Treatment Compared to 3-day Treatment With Valacyclovir in Adults With Recurrent Genital Herpes

NCT00306787
View directory record Official record
Conditions
Genital Herpes
Interventions
Famciclovir, Valacyclovir, Placebo matching famciclovir, Placebo matching valacyclovir
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
51
States / cities
Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2011 · Synced Nov 3, 2026, 4:05 PM EST
Completed Phase 2Phase 3 Interventional Results available

A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects

NCT02486406
View directory record Official record
Conditions
Chronic Hepatitis C Infection
Interventions
Ombitasvir/paritaprevir/ritonavir, Dasabuvir, Ribavirin, Ombitasvir mini tablet, Paritaprevir mini tablet, Ritonavir mini tablet, Dasabuvir mini tablet, Ribavirin solution
Drug
Lead sponsor
AbbVie
Industry
Eligibility
3 Years to 17 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
11
States / cities
San Francisco, California • Aurora, Colorado • Gainesville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2021 · Synced Nov 3, 2026, 4:05 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluate Safety, Tolerability, PK of TBAJ-876 in Healthy Adults

NCT04493671
View directory record Official record
Conditions
Pulmonary Disease, Tuberculosis, Pulmonary, Tuberculosis, Multi Drug Resistant Tuberculosis, Drug Sensitive Tuberculosis, Drug-resistant Tuberculosis, Mycobacterium Tuberculosis Infection
Interventions
TBAJ-876 suspension, Placebo suspension, TBAJ-876 100 mg tablet, TBAJ-876 25 mg tablet
Drug
Lead sponsor
Global Alliance for TB Drug Development
Other
Eligibility
19 Years to 50 Years
Enrollment
137 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Nov 3, 2026, 4:05 PM EST
Terminated Phase 2 Interventional

Efficacy and Safety Study of Low-Dose Ondansetron For Adjunctive Therapy In Adult Patients With Obsessive-Compulsive Disorder

NCT01275248
View directory record Official record
Conditions
Obsessive-compulsive Disorder
Interventions
Ondansetron, Placebo
Drug
Lead sponsor
Transcept Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
22
States / cities
Beverly Hills, California • Imperial, California • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2013 · Synced Nov 3, 2026, 4:05 PM EST
Recruiting Phase 4 Interventional

A Bundled Intervention to End Opioid Overdoses

NCT07485335
View directory record Official record
Conditions
Opioid Use Disorder, Opioid Overdose
Interventions
Bundled intervention (Experimental), control group, Buprenorphine (Experimental), Scheduled Peer Support Specialist (Experimental), Telemedicine Buprenorphine Treatment
Other · Drug · Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Nov 3, 2026, 4:05 PM EST
Completed Phase 4 Interventional Results available

Goal Achievement After a Change to Vortioxetine in Adults With Major Depressive Disorder

NCT02972632
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Vortioxetine
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 65 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
25
States / cities
Costa Mesa, California • Culver City, California • Glendale, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2019 · Synced Nov 3, 2026, 4:05 PM EST
Active, not recruiting Phase 2 Interventional

Phase II Study of Neoadjuvant ArOMatase Inhibitor Therapy for ER+ Breast Cancer (NAOMI)

NCT04568616
View directory record Official record
Conditions
Breast Cancer, ER Positive Breast Cancer
Interventions
Letrozole 2.5mg
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
2
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Nov 3, 2026, 4:05 PM EST
Completed Phase 2 Interventional Results available

Study To Evaluate Safety and Efficacy of Vesatolimod for the Treatment of Chronic Hepatitis B Virus in Virally-Suppressed Participants

NCT02166047
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
Vesatolimod, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
9
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2020 · Synced Nov 3, 2026, 4:05 PM EST
Completed Phase 1 Interventional Results available

MitoQ for the Treatment of Metabolic Dysfunction in Asthma

NCT04026711
View directory record Official record
Conditions
Asthma, Obesity
Interventions
Mitoquinol, Placebo oral tablet
Drug
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Durham, North Carolina • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Nov 3, 2026, 4:05 PM EST
Completed Phase 4 Interventional Results available

Study of Sustained Benefit of AMG334 in Adult Episodic Migraine Patients

NCT03927144
View directory record Official record
Conditions
Episodic Migraine
Interventions
AMG334, Oral Prophylactic
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
621 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
20
States / cities
Stanford, California • New Haven, Connecticut • Stamford, Connecticut + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Nov 3, 2026, 4:05 PM EST
Completed Phase 2 Interventional Results available

A Study to Test How Taking BI 1015550 for 12 Weeks Affects Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

NCT04419506
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
BI 1015550, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
11
States / cities
Clearwater, Florida • Gainesville, Florida • Kansas City, Kansas + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2022 · Synced Nov 3, 2026, 4:05 PM EST
Terminated Phase 4 Interventional Results available

Evaluating Metabolic Mechanisms of Ertugliflozin in Diabetes & Heart Failure

NCT04071626
View directory record Official record
Conditions
Heart Failure, Diastolic, Diabetes Mellitus, Type 2
Interventions
Ertugliflozin 5 mg, Placebo oral tablet
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 13, 2023 · Synced Nov 3, 2026, 4:05 PM EST
Withdrawn Phase 3 Interventional

Efficacy of Coenzyme Q10 Supplementation on Multi-Organ Dysfunction in Severely Burned Patients

NCT03968640
View directory record Official record
Conditions
Multiple Organ Failure
Interventions
CoQ10, Placebo
Dietary Supplement
Lead sponsor
American Burn Association
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 20, 2023 · Synced Nov 3, 2026, 4:05 PM EST
Recruiting Phase 2 Interventional

PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)

NCT07222215
View directory record Official record
Conditions
Estrogen-receptor-positive Breast Cancer, Metastatic Breast Cancer, Breast Cancer, Hormone Receptor Positive Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, HER2- Breast Cancer, ESR1 Gene Mutation, ER Wildtype, Breast Neoplasms
Interventions
Capecitabine, Elacestrant
Drug
Lead sponsor
Kristina A. Fanucci
Other
Eligibility
18 Years and older
Enrollment
297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Nov 3, 2026, 4:05 PM EST
Completed Phase 2 Interventional Results available

Study of VX-809 Alone and in Combination With VX-770 in Cystic Fibrosis (CF) Patients Homozygous or Heterozygous for the F508del-CFTR Mutation

NCT01225211
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Lumacaftor, Ivacaftor, Lumacaftor Placebo, Ivacaftor Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years and older
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
38
States / cities
Birmingham, Alabama • Anchorage, Alaska • La Jolla, California + 35 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2015 · Synced Nov 3, 2026, 4:05 PM EST
Completed Phase 3 Interventional Results available

A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH)

NCT00810693
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Riociguat (Adempas, BAY63-2521), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 80 Years
Enrollment
445 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
18
States / cities
Tucson, Arizona • La Jolla, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2023 · Synced Nov 3, 2026, 4:05 PM EST
Not listed Not applicable Interventional Accepts healthy volunteers

Metanx Effects on Nerve Fiber Density in Neuropathic Diabetics

NCT01503892
View directory record Official record
Conditions
Diabetes, Peripheral Neuropathy
Interventions
Metanx, Placebo
Dietary Supplement · Drug
Lead sponsor
St. Luke's Hospital and Health Network, Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2011
U.S. locations
1
States / cities
Bethlehem, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 17, 2012 · Synced Nov 3, 2026, 4:05 PM EST
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Thrombocytopenia and Bleeding in Wiskott-Aldrich Syndrome (WAS) Patients

NCT00909363
View directory record Official record
Conditions
Wiskott-Aldrich Syndrome, Thrombocytopenia, Bleeding
Interventions
Promacta, blood drawing in patients with WAS, blood drawing in healthy controls
Drug · Diagnostic Test
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
3 Months to 80 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 18, 2019 · Synced Nov 3, 2026, 4:05 PM EST
Terminated Phase 3 Interventional Results available

A Study To Evaluate The Safety Of Voriconazole As Treatment Of Invasive Aspergillosis (Fungal Infection) And Other Rare Molds In Children

NCT00836875
View directory record Official record
Conditions
Invasive Aspergillosis
Interventions
Voriconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
2 Years to 17 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
9
States / cities
Los Angeles, California • Oakland, California • Pittsburgh, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2017 · Synced Nov 3, 2026, 4:05 PM EST
Completed Phase 2 Interventional

A Study to Evaluate Safety and Efficacy of Toreforant (JNJ-38518168) in Participants With Moderate to Severe Plaque-type Psoriasis

NCT02295865
View directory record Official record
Conditions
Psoriasis
Interventions
JNJ-38518168 60 mg, JNJ-38518168 30 mg, JNJ-38518168 3 mg, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
10
States / cities
Los Angeles, California • Santa Monica, California • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2017 · Synced Nov 3, 2026, 4:05 PM EST
Terminated Phase 3 Interventional

Evaluation of Efficacy and Safety of AVE5530 in Patients With Primary Hypercholesterolemia

NCT00718965
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
AVE5530, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
826 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 16, 2016 · Synced Nov 3, 2026, 4:05 PM EST